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ABSTRACT
There is increasing clinical use of combined positron emission tomography and MRI, but to date there has been no clinical
system developed capable of simultaneous single-photon emission computed tomography (SPECT) and MRI. There has been
development of preclinical systems, but there are several challenges faced by researchers who are developing a clinical
prototype including the need for the system to be compact and stationary with MRI-compatible components. The limited work
in this area is described with specific reference to the Integrated SPECT/MRI for Enhanced stratification in Radio-chemo
Therapy (INSERT) project, which is at an advanced stage of developing a clinical prototype. Issues of SPECT/MRI compatibility
are outlined and the clinical appeal of such a system is discussed, especially in the management of brain tumour treatment.
INTRODUCTION
Hybrid clinical systems with the combination of X-ray com-
puted tomography (CT) and either single-photon emission
computed tomography (SPECT) or positron emission to-
mography (PET) have been commercially available since
1999/2000 and have found important roles in clinical prac-
tice1. The combination of clinical PET with magnetic reso-
nance imaging (MRI) was more recent, necessitating the
development of MRI-compatible components that support
simultaneous acquisition.2–4 At the time of writing, however,
the combination of SPECTand MRI in a simultaneous clinical
system had yet to be achieved, although work is in progress to
produce a functional prototype. This article provides an
overview of this relatively new area of development and an
insight into the challenges faced by researchers who are ac-
tively developing these systems. The coverage will summarize
the limited literature on SPECT/MRI technology, using as an
example the clinical design adopted in an ongoing project
(INSERT) funded under the European Commission FP7
framework. In this project, the researchers aimed to construct
the world’s first prototype clinical brain SPECT insert suitable
for simultaneous use with an existing MRI. As in the case of
the first clinical PET/MRI systems which were based on
dedicated brain PET inserts, this system is a first step towards
the potential development of a whole-body SPECT system
which would have wider application.
There are some major technological challenges in achieving
truly simultaneous SPECT/MRI, not least the need for MRI
compatibility and MRI safety of components and electron-
ics. Similar challenges have been faced by developers of PET/
MRI, with the adoption of MRI-compatible readout as
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replacement for the conventional photomultiplier tube (PMT).5,6
However, the need for compact detectors that include collimation
and stationary tomographic acquisition impose additional con-
straints on the MRI-compatible SPECT system design. A se-
quential preclinical SPECT/MRI system is already commercially
available and a number of preclinical synchronous SPECT/MRI
experimental systems have been built in recent years, but these
tend to rely on pinhole collimation with magnification, which
mainly suits small objects.7–9 Developing a clinical system has
required considerable innovation in many aspects of the design.
This article is structured as follows. The options for detector
design are discussed, including a description of customized
silicon photomultipliers (SiPMs) designed specifically for use
in SPECT. The possible collimator designs and overall system
design are discussed and MRI compatibility of components
including electronics is considered. Finally, the potential
applications of such systems are presented along with a brief
discussion on the pros and cons of such a system.
SPECT DETECTORS FOR SIMULTANEOUS
SPECT/MRI
In the case of the early development of PET/MRI, a compact brain
PET insert was designed that could be utilized with an existing
commercial MRI system.10 This then led to the development of
more integrated systems suitable for whole body scanning.11 A
similar strategy for the development of SPECT/MRI can be
adopted. One of the major constraints to be solved in the de-
velopment of an integrated SPECT/MRI system is the design of
a compact gamma detection module which exhibits mutual com-
patibility with commercial MRI scanners. PMTs are the photo-
detectors most commonly used in conventional SPECT systems.
Unfortunately, PMTarrays are too bulky to be fitted inside an MRI
bore and their performance is severely affected by the high mag-
netic field and the pulsed magnetic field gradients used in MRI.
Several solutions have been suggested. The first approach considers
the placement of magnetic-sensitive devices, such as PMTs, far
enough from the MRI apparatus, with light carried from the
scintillators to the photo detectors through long optical fibres.12,13
Another approach is based on the adoption of either pixelated
solid-state detectors [e.g. cadmium telluride (CdTe), cadmium zinc
telluride (CdZnTe or CZT)]7,14–16 or inorganic scintillators coupled
to solid-state photodetectors (e.g. avalanche photodiodes or
SiPMs).17–19 Digital SiPM technology has also been developed,
where on-chip circuitry enables fast, accurate photon counting and
well-defined timing.20 In combination with compact readout
electronics, these solutions provide compatibility with high mag-
netic fields and compact designs that are suitable for use within
MRI bore sizes of 60–70 cm commonly used in clinical practice.
A strong case has been made for the adoption of SPECT/MRI for
preclinical use.14 In most of the experimental synchronous pre-
clinical SPECT/MRI systems under study, arrays of CdTe or CdZnTe
(CZT) gamma detectors are employed,21,22 Similar solid-state
technology is finding increasing use in clinical SPECT systems be-
ing used for cardiac imaging,23,24 scintimammography25 and, more
recently, whole-body SPECT imaging.26 As regards compatibility
with MRI, preliminary investigations on CdTe and CZT have shown
that a shift of the signal charge inside the detector caused by Lorentz
forces takes place and this phenomenon requires correction to
improve the detector response so as to achieve a high resolution.9
An alternative for use in SPECT/MRI is the employment of
SiPMs to read out the light emitted by inorganic scintillators.27
Beyond the wide success of such detectors in MR-compatible
PET systems,28–30 there are several SPECT development projects
reported in the literature, exploring SiPM-based gamma de-
tector modules.31–34 The goal of these researchers was to pro-
duce compact gamma cameras for use in surgery or small organ
imaging. These systems have not normally been developed
specifically for MRI compatibility and are not tomographic, but
similar compact technology could be adapted for use in syn-
chronous SPECT/MRI. SiPMs show no intrinsic sensitivity to
magnetic fields, an important argument for the usage of a SiPM-
based gamma camera in combination with MRI.6 Although the
energy resolution of a scintillation-based system is typically in-
ferior to that offered by CdTe and CZT, it is still adequate to
potentially allow specific clinically important multi-radionuclide
acquisitions (e.g. 99mTc and 111In, 99mTc and 201Tl).
A disadvantage of pixelated detectors is that they involve direct
readout for each pixel; the number increases as the pixel size is
decreased. In comparison, a SiPM readout system with multi-
plexing requires a relatively small number of direct electrical con-
nections, since the readout units are quite large compared with the
resolution (at least an order of magnitude larger). This opens the
possibility to reach a given spatial resolution with a significant
reduction in the number of electronic readout channels (a factor of
100) compared with a pixelated detector with the pixel size equal
to the desired resolution.38 This advantage will be particularly
important in the translation of this technology for clinical appli-
cation. For a scintillator in combination with SiPMs, sufficiently
high intrinsic spatial resolution is achievable (approximately
1 mm) to enable compact SPECT designs, taking advantage
of multiple apertures with minification.35–37
SPECT/MRI SYSTEM DESIGN
Sequential SPECT and MRI has been performed with small-
animal SPECT adjacent to a low-field (0.1 T) MRI system,39
a solution still limited by the lack of simultaneity and by the
need for a low magnetic field. Several groups have designed
MRI-compatible preclinical systems. The design of an MRI-
compatible SPECT system for mouse brain imaging has been
Figure 1. A full preclinical ring populated with 10 gamma
detection modules. The mechanical structure also supports the
cooling distribution tubes and the power and optical commu-
nication lines. The overall diameter of the insert is 20cm.
l
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presented together with results of the effect of SPECT and MRI
components on each other.7 This early development led to more
recent construction of an ultrahigh-resolution stationary
MRI-compatible SPECT system for small animal imaging,
based on CdTe/CdZnTe detectors.22 Further preclinical
systems have been developed through academic/industrial
collaborations and the SPECT–MRI interaction has been
evaluated.8,40–42 A preclinical SPECT system has been
designed using Lutetium Yttrium Orthosilicate and digital
SiPM;43 the high-density detector enables use of a thin
detector for SPECT with the potential to reduce depth of
interaction effects that are common with pinhole collimation.
However, the light output is somewhat compromised for low-
energy gamma emitters. A preclinical prototype based on
SiPM readout has also been developed in the INSERT pro-
ject,44 with modular detectors that also suit a clinical SPECT
design (Figure 1). First images from the preclinical system
have been recently demonstrated.10
At the time of writing, the only commercially available preclinical
SPECT/MRI system (nanoScan® SPECT/MRI 1.0 T; Mediso,
Budapest, Hungary) was an inline system that uses a combination
of high-resolution multipinhole apertures, a PMT-based con-
ventional SPECT detection module and a specially developed
shielding system combined with a self-shielded 1.0 T permanent
magnet. This combination has been proven to yield a high SPECT
image quality and high-resolution imaging possibilities coupled
with a user-friendly and biologically relevant series of MRI
sequences. However, inline SPECT/MRI still lacks the advantages
presented by synchronous SPECT and MRI acquisition.
At the time of writing, there was publication of only one clinical
SPECT/MRI under construction (INSERT)25 dedicated to human
brain imaging. The system has been designed using stationary
rings of detector modules, designed so as to minimize variation in
the components when translating from the preclinical to the
clinical configuration. The electronic board, for SiPM signal
processing and transmission through optical fibres, also provides
mechanical support for a modular number of compact SiPM
arrays supplied by FBK, Trento, Italy.44 The SiPM arrays are
arranged in tiles to cover the required detector area: 53 5 cm2 for
the preclinical configuration and 103 5 cm2 in the clinical case
(Figure 2). An 8-mm-thick CsI(Tl) monolithic scintillator is
optically coupled over the overall SiPM matrix surface.
The detection module performance is mainly determined by
the amount of light detected by the SiPM array. Since SPECT
involves use of radionuclides with relatively low emission
energy, a low amount of light is generated for any scintillation
event. Thus, the following design principles have been
employed:
(1) A CsI(Tl) scintillator has been adopted. CsI has a high light
output and, although it is one of the slowest inorganic
crystals, the timing performance of the camera is sufficient
to handle the expected clinical countrate.
(2) The gaps between SiPM cells have been minimized through
a set of smart strategies in SiPM alignment.44 As a result, loss
in light detection has been significantly reduced.
(3) SiPM technology with optimal optical detection efficiency
has been chosen, specifically adapted to the optical
wavelength for CsI scintillation.
At room temperature, the presence of thermal noise results in
deterioration of the energy resolution, necessitating cooling of
the SiPM array. The detector module therefore incorporates
a compact 8-mm-thick cooling block made of MR-compatible
thermoplastic (Coolpoly®; Cool Polymers, North Kingstown,
RI), placed between the SiPM array and the electronic readout
board and designed to ensure uniform temperature control over
the SiPM area (Figure 3). A glycol–water mixture is circulated to
maintain the operating temperature of 0 °C. Image quality over
the single gamma detection module has been tested with 99mTc
(Figure 4). The intrinsic spatial resolution of the device is ap-
proximately 1.0mm full width at half maximum over a planar
field of view (FOV) of slightly greater than 43 4 cm2.
The clinical system design is illustrated in Figure 5. This is
based on use of 20 detector modules arranged in a partial
ring, designed to maximize the patient aperture with minimal
alteration to the existing patient bed. The key to development
has been the choice of a collimator, which has been designed
to provide maximum axial coverage and optimal sensitivity,
while maintaining reconstructed resolution so as to be similar
to conventional gamma camera SPECT. The reason for this
target was the intention to explore the use of the technology
to characterize and evaluate treatment in well-identified
brain tumours rather than to optimize detection of small
abnormalities.
COLLIMATORS FOR CLINICAL SPECT SYSTEMS
The design of a compact clinical system is markedly different
from the typical preclinical designs where multipinhole col-
limators usually take advantage of magnification to achieve
superior resolution. With improvement in intrinsic resolu-
tion, the degree of magnification can be reduced so as to
achieve the desired compact design. Similar designs have been
Figure 2. The three-side-tilable silicon photomultiplier arrays
composing the planar detector field of view in the preclinical
case. The dead detection area of the single array has been
minimized to increase the amount of luminous signal collected.
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adopted to achieve superior resolution for clinical brain
SPECT [(G-SPECT; MiLabs, Utrecht, Netherlands) (AnyScan
Trio; Mediso)]; however, these systems are not compact.
Instead, the improvement of intrinsic resolution using the
new technology can be used to advantage by adopting mini-
fication as opposed to magnification so that the resolution is
effectively traded against compactness, to achieve similar
performance to a conventional gamma camera SPECT system.
The main challenges in collimator design are to construct
a compact system with sufficient angular sampling to permit
stationary acquisition (avoiding detector movement is highly
desirable for simultaneous SPECT/MRI acquisition). Van
Audenhaege et al45 proposed a design for a multipinhole colli-
mator for performing clinical brain SPECT studies using an
existing PET scanner. The collimator was equipped with
a shutter mechanism, in order to eliminate the need for rotation;
however, the prototype was not MR-compatible. Preclinical
systems usually utilize multipinhole collimators;46,47 but, for
a compact clinical system, preference was given to utilizing
a multislit-slat collimator (Figure 6), which incorporates several
novel features. The slits are located internal to the slats so as to
achieve the desired minification without compromising slat
length (which controls the axial resolution/sensitivity trade-off).
Multiple short slits are employed to improve the angular sam-
pling and slits are shared across detectors so as to accommodate
the desired FOV. The resulting collimator37 demonstrates higher
sensitivity than alternative multipinhole collimators and also
improves on fan beam collimation, which is commonly used on
conventional SPECT.
A further consideration in collimator design is the choice of
material and the avoidance of features which might result in
induced eddy currents. The rapid switching of gradient coils
induces spatially and temporally varying eddy currents within
the conducting structures of the MRI scanner and in the colli-
mator required for SPECT, which typically has a high conduc-
tivity. The undesired magnetic field produced by these eddy
currents opposes and distorts the linear gradient fields in the
region of interest, which results in image artefacts.48 Other
effects concern the thermal load in the cryostat of the super-
conducting magnet, which may lead to increased boil-off of the
cryogens (can even cause magnetic quenching in extreme cases)
and acoustic noise due to their interaction with the B0 field.
49
The material traditionally used for collimators and shielding is
lead, strengthened by various impurities that tend to be ferro-
magnetic. The alternative is to use tungsten and several groups
have developed tungsten/epoxy composites in an attempt to
Figure 3. INSERT gamma camera configured for preclinical SPECT. In the violet box, the 36-channel application-specific integrated
circuit (ASIC) for signal readout and filtering is depicted. Digitized SPECT signals are transmitted through optical fibres.
Temperature is stabilized at 0 °C by the cooling unit (an aluminium version of the unit is depicted). SiPM, silicon photomultiplier.
Figure 4. Planar irradiation profile for a 535cm field of view of the preclinical INSERT detector module. (a) A lead grid of holes
(0.5mm in diameter, 2mm pitch) is employed to collimate the gamma rays. (b) Experimental result for 99mTc: the event coordinates
were reconstructed using a maximum likelihood method. FWHM, full width at half maximum.
l
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reduce eddy currents while maintaining stopping power.50 This
strategy works well for radiation shielding, with attenuation
approaching that of lead being possible. However, the composite
material tends to be brittle and easily broken and so not suitable
for fine collimator components.
Various strategies can be employed in the design of pinhole
collimators to reduce the incidence of eddy currents, e.g. seg-
menting the collimator into smaller subsections while avoiding
any possible penetration.51 Manufacturing the resulting complex
parts is greatly aided by recent developments in additive
manufacturing.52 In the case of already complex multicompo-
nent tungsten collimators (e.g. multislit-slat collimators), in-
duced eddy currents appear to be acceptably small.
SPECT/MRI COMPATIBILITY
The technical challenges of integrating a SPECT insert with
a clinical MRI system relate primarily to potential interferences
between both modalities. These interferences might compromise
MR safety and MR compatibility. The requirements of MR safety
are met if the SPECT device poses no known hazards in
a specified MRI environment with specified conditions of use.
Conditions that define the MRI environment include static mag-
netic field strength, spatial magnetic field gradient, time-varying
magnetic fields and radiofrequency (RF) power deposition.
Additional conditions, including specific configurations of the
SPECT device (e.g. routing of leads and power lines), may be
required. MR compatibility indicates that a SPECT device, when
used in the MR environment, does not significantly reduce the
quality of the diagnostic information via the formation of MR
signal and image artefacts and that its operation will not be
detrimentally affected by the MR device.
Mutual SPECT/MRI safety and compatibility issues may
arise from:
– static magnetic fields (B0): interference with the B0 spatial
gradient can cause displacement and torque of objects moved
into the MR environment. This displacement force is
responsible for the projectile effect that continues to cause
accidents in the MR environment. Diagnostic MRI and MR
spectroscopy require a B0 uniformity of #1 ppm and foreign
objects such as bulk collimators, SPECT detector modules
and large bundles of lead placed in the MR magnet run the
potential to perturb B0. The static magnetic field might also
induce susceptibility effects which bear the risk of spoiling the
MR signal and image quality if placed close to the FOV used
for MRI. Sensitivity to B0 might also cause malfunction and
dysfunction of the SPECT device owing to electromagnetic
interference with its electronics and detectors.
– Switching magnetic fields (dB/dt: #200mT/m/ms): switch-
ing magnetic fields can cause movement, frequency shift and
temperature rise owing to eddy currents induced in
conductive system components (cables, collimator, cooling
blocks, means of shielding, scintillators etc.) placed inside
the magnet bore equipped with a gradient coil. Pulsed
magnetic field gradients might also interfere with the
electronic circuits and detectors of the SPECT device,
disturbing the low amplitude signals within the SPECT
acquisition chain (application-specific integrated circuit,
data acquisition board etc.).
– RF energy transmission (B1
1): RF transmission can induce
temperature rise and functionality disturbances owing to RF
power deposition. RF might also interfere with the electronics
and detectors of the SPECT device owing to RF shielding
deficits. Any RF emission of the SPECT device (for example:
power supplies or preamplifier electronics) bears the potential
Figure 5. (a) Schematic diagram of the clinical system design with a partial ring of 20 detectors. The patient aperture of 33cm
accommodates the MRI receiver/transmitter head coil. (b) Schematic of complete SPECT insert in the MRI system.
Figure 6. Multislit-slat collimator corresponding to three
detector units. The collimator consists of slats in the axial
direction and an array of short slits with their apertures internal
to the collimator surface. The figure shows a central slit (a) for
each of the three subsections plus slits that are shared across
adjacent detectors (b).
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to interfere with the MR device and compromise its
(diagnostic) functionality through RF-induced artefacts.
– Movement and flow: mechanical movement of components of
the SPECT device can cause MR frequency shift owing to
eddy currents. Flow (for example: cooling fluids) in the FOV
to be imaged can cause MRI artefacts that present an
impediment for diagnostic image quality. The implications
feed into the (stationary) collimator design and the cooling
strategy used for heat extraction from the SiPMs ther-
mal pads.
The literature primarily reports on evaluation of MR compati-
bility and safety of instruments for interventional MR
procedures53–56 and provides guidance for standardized test
procedures57–60 that mainly focus on passive devices. A SPECT
insert is an active device that differs from interventional MR
devices/applications in many aspects. For the design of a syn-
chronous clinical setup, careful considerations need to be made
to reduce if not eliminate electromagnetic coupling between the
MR and SPECT device with the goal to assure SPECT/MR
compatibility. These considerations should include legal regu-
lations61 and established norms,62,63 but should also build upon
a close interdisciplinary team work involving experts in electrical
engineering, SPECT manufacturing, RF antenna design, MR
physics, nuclear medicine and radiology. As a minimum, pro-
cedures for ensuring MR safety and compatibility should include
the following assessments.
Hard magnetic materials
Hard magnetic materials (also known as permanent magnets)
including high carbon steels, barium, ferrite, alnico, samarium–
cobalt alloys etc. are not MR-safe and should be strictly
banned from any clinical SPECT design. This test can be
conveniently performed by measuring the attraction force of
a piece of metal plate placed in the vicinity of the material
under investigation.
Soft magnetic materials
Soft magnetic materials are not magnetized if not placed in the
vicinity of a magnetic field. However, their susceptibility is very
large and they exhibit forces and torques in the presence of
a strong magnetic field of a clinical MR scanner.64 The test for
soft magnetic materials is performed according to the American
Section of the International Association for Testing Materials
(ASTM) Standard F2052-06.57 For example, WNiFe collimator
materials (alloy 1: r5 17.6 g cm23, W5 93%, Ni5 5%,
Fe5 2%; alloy 2: r5 18.0 g cm23, W5 95%, Ni5 3.5%,
Fe5 1.5%; Nuclear Fields International, Vortum-Mullem,
Netherlands) were found to be ferromagnetic and excluded from
the collimator design. In comparison, collimator samples of
polyimide/tungsten (r5 11.0 g cm23), lead 1 4% antimony
(r5 11.03 g cm23), lead (r5 11.3 g cm23) and tungsten
(r5 19.3 g cm23) are non-magnetic.
Non-magnetic materials
Non-magnetic materials exhibit small magnetic susceptibility x so
that no forces and torques are apparent when placed in a static
magnetic field. To avoid any B0 perturbation induced by the
magnetic susceptibility of the SPECT insert, the ideal magnetic
susceptibility would be xSPECT insert5xair5 0.363 10
26 which is
hard to achieve in practice.64 The effects of magnetization
induced by non-magnetic materials/objects used for the SPECT
insert are largest at the surface of the object. Therefore, it is
prudent to place all components of the SPECT system outside
of the FOV of the MR system for avoiding susceptibility
gradient-induced artefacts. The tests for magnetic susceptibility
are based on the ASTM Standard F2119-0758 and on the study
of Wendt.65 To achieve this goal, a material probe together with
a reference probe (e.g. copper) is placed in close proximity to
an imaging phantom65 filled with a solution.58 MR scans are
performed for multiple orientations to evaluate the severity
and extent of magnetic field distortion and susceptibility
artefacts induced by the material under investigation vs the
reference probe (Figure 7).
Frequency shift and free induction decay
attenuation due to eddy currents induced by pulsed
magnetic field gradients
Local eddy currents disturb B0 homogeneity resulting in fre-
quency shift, T2* relaxation time shortening and free induction
decay (FID) attenuation. For eddy current and frequency as-
sessment, a reference FID/spectrum is acquired for an agarose
phantom. For comparison, the object under test is placed in the
magnet (resembling its position in the SPECT insert) followed
by the acquisition of a test FID/spectrum. For both sets of
measurements, the delay between the pulsed magnetic field
gradient and the FID acquisition is varied to determine the eddy
current time constant (Figure 8). Eddy current considerations
have major implications for the design of the heat exchangers,
since commonly employed copper heat exchangers (which ex-
hibit very good thermal conductivity 401W/mK21) cannot
be implemented. To overcome this limitation, thermally
conductive non-metallic materials, such as ceramic material
SHAPAL™ (Precision Ceramics, Birmingham, UK) (thermal
conductivity 92 W/mK21) or thermally conductive plastic
CoolPoly® D5506 (Cool Polymers, North Kingstown, RI)
(thermal conductivity 10 W/mK21), are alternative candi-
dates for the cooling block material. The latter is less costly
and can be easily modelled in complex forms with robust and
reliable outcomes.
Heat extraction and spurious MR signals
From the MR perspective, air cooling can be considered as an
ideal candidate for heat extraction from the SiPM thermal pads,
since air does not induce spurious MR signals. However, air
cooling constitutes a severe challenge for flow and temperature
stabilization needed for the SiPM performance. For this reason,
a water and glycol mixture (40–60%) is used for heat extraction
from the cooling block. To reduce spurious MR signals, the RF
coil is shielded. Also, the tubes supplying and draining the
heating blocks need to be routed outside of the excitation field
of the RF coil to avoid spurious signals in the MR images. The
remaining concern is spurious MR signals due to aliasing of
the parasitic signal obtained from the cooling fluid outside of
the FOV into the FOV. This artefact is induced by parasitic
excitation of regions outside of the FOV owing to the non-
linearity of the gradient coil, and commonly called “third arm
artefact”. Parasitic excitation can be addressed by limiting
Br J adiol;90:
7 of 13 birpublications.org/bjr Br J Radiol;91:20160690
Physics and instrumentation special feature review article: Development of clinical simultaneous SPECT/MRI BJR
the range of excitation and reception of the RF coil using
a dome-shaped design or by employing a bird cage design
tailored to the brain.
Mechanical vibration due to pulsed magnetic
fields gradients
The literature is short of a standardized test given by ASTM or
other bodies that is tailored for examining mechanical vibration
induced by a device incorporated or inserted in an MR scanner.
Careful considerations should include the use of pressure and
acceleration sensors. It is advised that the eigenfrequencies of the
SPECT components should not match the frequencies of the
magnetic field gradient-switching schemes used for MRI to
avoid strong coupling.
Temperature changes due to pulsed magnetic
fields gradients
Under normal conditions, the heating due to pulsed magnetic
field gradients in the kilohertz frequency range is negligible.66
This may change if bulky electrically conductive objects (colli-
mator, cooling blocks, application-specific integrated circuit
etc.) are placed in the MR scanner. For temperature monitoring,
an object under test is placed either in air or in a gel
phantom59,67 and positioned in the MR scanner according to its
Figure 7. Magnetic field distortion inside a uniform phantom due to the presence of a collimator block (polyimide/tungsten,
r5 11.0gcm23) tested for the clinical SPECT/MRI setup. The left image shows a uniform static magnetic field in the absence of the
collimator block. For this setup, a magnetic field dispersion (Df) of approximately 20Hz was obtained across the slice. After placing
the collimator block in close vicinity to the phantom lower right corner, the static magnetic field is significantly distorted (right)
which manifests itself by field dispersion across the slice of Df  120Hz.
Figure 8. An example of eddy current assessment using a reference free induction decay (FID) (black line) obtained for an agarose
phantom and pulsed magnetic field gradients placed along the read, phase and slice direction. For comparison, the object under
test [polyimide/tungsten sample (r5 11.0gcm23] was placed in the magnet (resembling its position in the SPECT insert) followed
by the acquisition of a test FID (blue and red lines). For assessment of the eddy current time constants, the delay between the
pulsed magnetic field gradient and the FID acquisition was varied between 0.3 and 300ms.
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position within the SPECT system. Temperature probes are at-
tached to the object and positioned in its vicinity. Pulsed magnetic
field gradients are applied using clinical MR protocols including
fast spin-echo, fast gradient-echo and echoplanar imaging
sequences for fast and high duty cycle switching paradigms.
Pulsed gradient fields
Pulsed gradient fields can induce electrical voltages on the
SPECT device components as well as on all electrical cables
connected to them. These voltage spikes interfere with device
operation and can cause measurement artefacts in the form of
spectral distortions and can even lead to a complete operational
failure if voltages become too high. Electromagnetic simulations
and bench measurements using pulsed magnetic field generators
such as toroidal coils are performed to test problematic con-
figurations and identify possible mitigation measures.
SPECT/MR interferences due to radiofrequency
transmission/emission
This compatibility issue can be twofold: (i) interference of RF
coil transmission with the functionality of the SPECT modules
and (ii) interference of RF emission induced by the SPECT
device with the RF chain of the MR scanner. To reduce RF
interferences caused by the SPECT module, it needs to be
electromagnetic compatibility shielded. Efficiency of electro-
magnetic compatibility shielding can be evaluated by placing the
components of the SPECTelectronics in a shielded box followed
by measurements of RF spectra outside of the box (Figure 9).
The RF coil itself is shielded and, in addition, is separated from
the active components of the SPECT system by a collimator,
which reduces (if not eliminates) RF interference with the
SPECT device. For the evaluation of MRI/SPECT interferences,
it is prudent to use a transmitted RF power that exceeds the
limits given by the International Electrotechnical Commission
guidelines by a factor of 3. For the assessment of SPECT/MRI
interference, noise figures are acquired. For this purpose, the
component under investigation is placed in the MR system with
the collimator (or alternative shielding) being installed. An RF
coil and an MRI phantom are placed inside the collimator. A
noise scan and clinical imaging protocol are performed, while the
component under test is in operation. These scans are bench-
marked against reference data acquired without the component
under investigation in the bore.
Radiofrequency heating induced by the
radiofrequency transmission
In current clinical MR scanners, integrated large-volume body RF
coils are commonly used for RF excitation. The large-volume
excitation bodes well for a uniform transmission field. Yet, this
approach is not suitable for a clinical SPECT/MR setup owing to
the RF shielding provided by the collimator and other compo-
nents of the SPECT insert. Instead, a small-volume transmit
transmit/receive RF coil tailored to the geometry of an average
head and positioned inside the SPECT insert is employed. The RF
power applied to this RF coil needs to be limited to meet the RF
power deposition and specific absorption rate limits governed by
the International Electrotechnical Commission guidelines.68 For this
purpose, careful electromagnetic field simulations need to be con-
ducted in human voxel models. For validation, transmission field
distributions obtained from these simulations need to be bench-
marked against experimental B1
1 maps.69,70 Since the integrated
SPECTmodule is placed outside of the RF coil, it is unlikely that the
head coil of the MR scanner would induce heating into the SPECT
module that might cause a compatibility issue.
Potential applications of clinical SPECT/MRI
In general, it is the authors’ opinion that multi-radionuclide
SPECT imaging with well-established radiopharmaceutical
tracers of a variety of metabolic and molecular features could
indeed provide useful synergies with function-related physi-
ometabolic MRI and spectroscopy including X-nuclei MRI.
Owing to the massively multiarray possibilities of the resulting
images, synchronous SPECT/MRI realizes insights hereto im-
possible for any other type of hybrid imaging methodologies
(including PET/MRI). As nowadays fully quantitative SPECT
reconstruction can be achieved, synchronous SPECT/MRI
Figure 9. A data acquisition board mounted inside the electromagnetic compatibility shielding test box for the evaluation of the
SPECT/MRI interference due to radiofrequency emission (left). Closed test box being fully shielded (right).
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equipped with high temporal resolution acquisition will be the
method of choice for personalized therapy guidance and
“radiomics”-based decisions (i.e. use of imaging parameters as
a surrogate for reading out tumour biology).
One goal of the current synchronous SPECT/MRI development
is to aid in the clinical management of patients with brain
tumours. Assessment of treatment response in patients with
glioma is currently extremely challenging. Anatomical and
contrast-enhanced MRI remains the standard imaging modality
at follow-up, but is associated with well-documented problems
in ascertaining response to treatment, particularly at early time
points owing to the phenomenon of pseudoprogression71 as-
sociated with inflammation. Currently, patients with imaging
findings that suggest progression or pseudoprogression are
managed expectantly, since the only approach to confirming the
diagnosis is through continued clinical and radiological follow-
up. It is notable that fluorodeoxyglucose (18F-FDG) imaging has
not proven useful for this indication, although amino acid
tracers may be more relevant and are still under investigation in
this setting.72,73 Hence, based on current imaging approaches,
patients who have true progression may be denied access to
alternative treatments early and patients who will have an ulti-
mately favourable outcome cannot be reassured. In the context
of pseudoprogression, the earlier the imaging is carried out
following treatment, the less useful the data tend to be and to
date, there have been no successful approaches to monitor these
patients during treatment. This is despite the fact that real-time
assessment of treatment response, for example during radio-
therapy or adjuvant chemotherapy, could allow for selection of
patients for treatment intensification at the time when treatment
is likely to be most effective.
The clinical use of simultaneous SPECT/MRI to directly help
assess (and thus predict) therapy monitoring will be most
prominently present in the imaging and follow-up of local or
systemic radionuclide therapy against post-surgical brain tu-
mour remnants.74–76 Dosimetry and efficacy control will be
possible with a SPECT/MRI system as opposed to PET/MRI,
given that therapeutic nuclides are mostly SPECT emitters too.
Improved dosimetry in the tumour is indispensable to optimize
radionuclide therapeutic procedures for reaching the highest
possible tumour dose. Improved regional dosimetry is necessary
to identify dose-related organ impairment risks too.
There is further potential for future use of specific radionuclide-
labelled peptides in targeted radionuclide therapy; provided that
single photon emission is present in either the therapeutic ra-
dionuclide or an available analogue, then patient-specific do-
simetry can be readily estimated. This would be an ideal use of
the SPECT/MRI combination. In the future, one can anticipate
availability of compounds that are labelled either with gamma
emitters for diagnostic purposes or with therapeutic radio-
nuclides; the ability to plan and monitor therapy with these
paired compounds has potential. If used for therapy, the com-
pound would be labelled with an alpha or beta emitter rather
than a gamma emitter; the gamma version would be used to
plan subsequent personalized therapy using the alpha or beta
emitter. One case is with 131I-labelled compounds; 123I labelling
can be used instead for therapy planning. The alternative use of
124I with PET is methodologically challenging and is limited by
both general availability and dosimetric issues. One emerging
example is targeted alpha therapy using 212Pb, where 203Pb is
proposed to be the surrogate dosimetry probe based on SPECT
imaging.77
Additional applications can be envisioned in research of the
central nervous system. Functional MRI brain mapping studies
combined with complementary, simultaneous SPECT readouts
of neuroreceptor pathways using radio-labelled receptor ligands
will be feasible with the system, although PET/MRI will probably
remain the preferred modality for these studies. In treatment of
diseases of the central nervous system (especially dementia),
intensive development of new therapies is under way. SPECT/
Figure 10. (a) 99mTc-labelled pentavalent dimercaptosuccinic
acid [99mTc-DMSA(V)] and gadolinium (Gd)-enhanced
gradient-echo three-dimensional (3D) sequence MRI visualizes
peripheral, more perfused regions of the tumour to express
more transporter proteins of phosphate ions related to
energy metabolism. Also, the superior nature of SPECT/MRI
with very high resolution and high soft-tissue details/
MRI-related functionality of the perfusion data readout is
presented. (b) 125I-deoxy-uridine and Gd-enhanced gradient-
echo 3D sequence MRI visualizes central, less perfused
regions of the tumour to express more DNA build-up
(nucleoside incorporation). This image was taken synchro-
nously with 99mTc-DMSA(V) images using an energy window
centred at 28 keV.
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MRI offers an outstanding opportunity for simultaneous
blood perfusion imaging and determination of other disease
indices such as dopamine transporter or neuroinflammation-
associated parameters. Here, Go/No-Go decisions of large
investments (in pharmaceutical discovery and development)
are dependent on early disease detection and the evaluation of
treatment effect. But, as suitable therapies are developed, the
demand for cost-effective tools will increase; SPECT/MRI
may be the system of choice for wider scale screening that
may be indicated.
DISCUSSION
There are several potential advantages offered by simulta-
neous acquisition of MRI and SPECT images, rather than
simply sequential acquisition via adjacent gantries (or totally
independent acquisition). The reduction of the overall scan
time and associated improvements in patient comfort and
compliance are important. The availability of registered data
sets to assist localization can be helpful, as it is not always
possible with separately acquired modalities, especially with
highly specific radiotracers where many structures may not
be visualized. However, the potential to combine information
from the two modalities so as to enhance diagnostic and
prognostic information is particularly appealing. This can
potentially extend beyond the improvement of SPECT
quantification via motion or partial volume correction (PVC)
to the development of joint models that might enhance both
SPECT- and MRI-derived parameters. There is a strong case
to evaluate the potential of this new multimodality option.
Both SPECT and MRI are lengthy procedures requiring patient
cooperation, but restricting motion for lengthy periods can be
a challenge, especially with certain brain conditions where
movement control is affected. Motion effects can therefore be
significant. Monitoring motion during SPECT acquisition is
therefore very important and will allow correction of motion
during reconstruction; this does imply that motion can be suf-
ficiently well monitored during the complete SPECT acquisition,
which should be possible using techniques being developed for
PET/MRI.78–80 For example, MRI navigator techniques can
monitor and correct for motion for predefined regions such as
the surface of the head, acquired in combination with most
standard MRI techniques that may be selected for clinical studies
(e.g. T1, T2). There are, however, challenges in accurately de-
termining the rigid motion based on six degrees of freedom and
alternative methods of motion tracking may be more appro-
priate, provided these can be implemented in the practical set-
ting, with minimal interference to the normal clinically
indicated MRI acquisition.
Much of the work on PVC has been developed for PET.
Traditionally, in the case of clinical systems, SPECT resolution
is inferior to that of PET. PVC for SPECT is therefore
more demanding but critical. Once again, the techniques that
have been developed for PET/MRI are easily adapted for the
SPECT/MRI application. The availability of simultaneous
SPECT and MRI data will greatly facilitate correction using
post-reconstruction methods,81 potentially reducing regis-
tration errors that affect PVC accuracy.
A distinct advantage of SPECT over PET is the potential for
simultaneous acquisition of multiple radiotracers labelled with
different radionuclides. Similar techniques in PET rely on se-
quential use of short half-life radionuclides and extrapolation of
time–activity curves. The ability to combine multitracer studies
with multiple MRI pulse sequences extends the potential to
better characterize tissue and evaluate treatment. A preclinical
example of combined multi-radionuclide imaging and MRI is
illustrated in Figure 10. Dual radionuclide imaging does require
corrections for downscatter, scattered photons from the higher
energy emitter that are acquired in the energy window selected
for the lower energy radionuclide. Correction is more complex
in the case of CZT, where a tail in the energy spectrum due to
incomplete charge collection must also be accounted for.82–84
A range of radiopharmaceuticals may be of interest for dual
radionuclide imaging (Table 1).
Table 1. Possible measurements using SPECT/MRI including a range of MRI biomarkers along with 99mTc-labelled compounds and
additional compounds with second radionuclide, which could be used interchangeably
MRI Application SPECT1 Application 1 SPECT2 Application 2
T1, gadolinium
enhancement
Tumour site, blood–brain
barrier integrity
99mTc-DMSA(V)
Phosphate
transport
201Tl-chloride
Perfusion/glial activity
(prognosis)
T2 1 FLAIR Invasiveness
99mTc-DTPA
Blood–brain
barrier integrity
111In-RGD peptide Angioneogenesis
MRI perfusion 1
T2 FLAIR
Invasiveness, oedema 99mTc-Annexin-V Apoptosis 123I-CLINDE
Histologic
classification
DWI 1 ADC
additive: DTI
Intracellular/extracellular
oedema, pseudoprogression
99mTc-HMPAO Perfusion 111In-Nimotuzumab
Planning for specific
treatment
MR spectroscopy Histologic classification 99mTc-HL91 Hypoxia 123l-iodoUracyl
Proliferation
post-therapy
ADC, apparent diffusion coefficient; DTI, diffusion tensor imaging; DWI, diffusionweighted imaging; FLAIR, fluid-attenuated inversion recovery; 123I-CLINDE,
123I-labelled 6-chloro-2-(49-iodophenyl)-3-(N,N-diethyl)imidazo[1,2-a]pyridine-3-acetamide; 111In-labelled arginyl-glycyl-aspartic acid (RGD) peptide; SPECT,
single-photon emission computed tomography; 99mTc-DMSA(V), 99mTc-labelled pentavalent dimercaptosuccinic acid; 99mTc-DTPA, 99mTc-labelled
diethylenetriaminepentaacetic acid; 99mTc-HL91, 99mTc-labelled 4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime; 99mTc-HMPAO, 99mTc-labelled
hexamethylpropyleneamine oxime.
Potential diversity of simultaneous measurement in the context of tumour characterization is well illustrated.
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There is still much to do to reach a stage of demonstrating robustness
of SPECT/MRI and evaluating its clinical utility. Whether solid-state
detectors or SiPM readout systems will become the design of choice
remains to be seen. Extension of design ideas to permit whole-body
acquisition may require a larger bore than typical of current MRI
systems. Wide bore systems are clinically appealing to ease patient
access and improve patient comfort; so, this MRI system de-
velopment may be dictated by independent clinical demands.
Early experience suggests that clinical performance similar to that
available on conventional SPECT systems should be possible with
relatively compact detector/collimator combinations, although fur-
ther innovation may be needed to address sampling issues when the
FOV is enlarged to accommodate the whole body.
CONCLUSION
The combination of SPECT and MRI is currently absent from
the range of clinical multimodality systems, although work is in
progress to produce the first prototype. As in the case of PET/
MRI, the combination of SPECT and MRI is attractive to
patients who often have to undergo multiple lengthy imaging
procedures. The dual radionuclide capability has particular ap-
peal, although the clinical need for a simultaneous SPECT/MRI
acquisition remains to be demonstrated. The development of
appropriate technology remains challenging, but ultimately may
lead to more general superior SPECT performance.
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